Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071747 · ClinicalTrials.gov registry record · Phase 3
Clinical Study Of Schizophrenia in Both Men and Women
A Phase 3 study of Schizophrenia, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 176
- Enrollment target
- 20
- Study locations
NCT00071747: Completed Phase 3 study of Schizophrenia, sponsored by GlaxoSmithKline.
NCT00071747 is a Phase 3 study of Schizophrenia that has completed, run by GlaxoSmithKline. The registered enrollment target is 176 participants, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00071747, a Phase 3 study of Schizophrenia, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 176 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entrance criteria will have an assessment 1-7 days after the first visit to confirm eligibility.
Conditions Studied
Interventions
- DRUG lamotrigine
Study Locations (20)
California
- GSK Investigational Site - Garden Grove
- GSK Investigational Site - La Mesa
- GSK Investigational Site - National City
- GSK Investigational Site - Oceanside
- GSK Investigational Site - Rosemead
- GSK Investigational Site - San Diego
Florida
- GSK Investigational Site - Maitland
- GSK Investigational Site - North Miami
Maryland
- GSK Investigational Site - Glen Burnie
- GSK Investigational Site - Rockville
New Jersey
- GSK Investigational Site - Clementon
- GSK Investigational Site - Kenilworth
New York
- GSK Investigational Site - Orangeburg
- GSK Investigational Site - Rochester
Arkansas
- GSK Investigational Site - Little Rock
Connecticut
- GSK Investigational Site - Hartford
Illinois
- GSK Investigational Site - Granite City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 176 participants |
| Start Date | 2003-08 |
| Est. Completion | 2005-01 |
| Phase | Phase 3 |
What the finished NCT00071747 record still lists
NCT00071747 is an interventional study that assigns participants to a tested intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (19% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which lamotrigine is the first listed.
NCT00071747 names 20 study sites across 11 states, led by California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT00071747 about?
NCT00071747 is a clinical study titled "Clinical Study Of Schizophrenia in Both Men and Women". The objective of this study is to evaluate the effectiveness of a marketed drug in the treatment of schizophrenia, as an add-on therapy to antipsychotics over a 12-week period. Subjects with schizophrenia who have been maintained on a stable dose of antipsychotics and who fulfill the screening entra...
What is the current status of trial NCT00071747?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 176 participants. The study started on 2003-08. Estimated completion is 2005-01.
What conditions does trial NCT00071747 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT00071747?
The interventions under investigation include: lamotrigine (DRUG).
Who is sponsoring clinical trial NCT00071747?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00071747 being conducted?
This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00071747's enrollment target sits among peer trials
176 94th of 315 higher than 222 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03304821 · 176 participants · Phase 2
Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease
- NCT03447938 · 176 participants · NA
The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial
- NCT03824145 · 176 participants · NA
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
- NCT04177914 · 176 participants · Phase 3
HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia